Last updated: August 1, 2026
Eplerenone is a selective mineralocorticoid receptor antagonist marketed primarily as a generic for hypertension and heart failure with reduced ejection fraction. Its original U.S. patents and regulatory exclusivities have expired, and generic competition limits pricing power. The drug retains clinical value because it reduces cardiovascular morbidity and mortality in selected heart-failure populations, but newer mineralocorticoid receptor antagonists, particularly finerenone, are expanding competition in cardiorenal disease.
What is eplerenone approved to treat?
Eplerenone is an oral selective aldosterone receptor antagonist. The U.S. Food and Drug Administration approved Inspra, the originator product, for:
| Indication |
FDA approval basis |
Clinical role |
| Hypertension |
2002 |
Blood-pressure reduction, generally as add-on therapy |
| Heart failure after acute myocardial infarction |
2003 |
Reduced cardiovascular mortality and hospitalization in patients with left-ventricular dysfunction and heart failure |
The FDA label recommends an initial dose of 25 mg once daily for post-myocardial-infarction heart failure, titrated to 50 mg once daily when tolerated. For hypertension, the usual starting dose is 50 mg once daily, with a maximum of 50 mg twice daily in selected patients. Hyperkalemia monitoring is required because eplerenone inhibits aldosterone-mediated potassium excretion (FDA, 2023).
Eplerenone is more selective for the mineralocorticoid receptor than spironolactone. That selectivity reduces antiandrogenic and progestational adverse effects, including gynecomastia and menstrual effects, but eplerenone generally has a higher acquisition cost than generic spironolactone and remains subject to hyperkalemia risk.
What clinical trials established eplerenone efficacy?
EPHESUS established post-infarction mortality benefit
The Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study randomized 6,632 patients with acute myocardial infarction, left-ventricular ejection fraction of 40% or less, and clinical heart failure or diabetes to eplerenone or placebo.
The trial reported:
| EPHESUS outcome |
Eplerenone result |
| All-cause mortality reduction |
15% relative reduction |
| Cardiovascular mortality or cardiovascular hospitalization |
13% relative reduction |
| Sudden cardiac death |
Reduced |
| Follow-up |
16 months median |
The mortality benefit was observed on top of contemporary post-infarction therapy, including beta blockers, ACE inhibitors, angiotensin-receptor blockers, and revascularization where appropriate (Pitt et al., 2003).
EMPHASIS-HF expanded use to chronic systolic heart failure
The EMPHASIS-HF trial evaluated 2,737 patients with New York Heart Association class II heart failure and left-ventricular ejection fraction of 35% or less. Eplerenone was added to standard therapy.
The primary composite of cardiovascular death or heart-failure hospitalization occurred in 18.3% of patients receiving eplerenone versus 25.9% receiving placebo. This represented a 37% relative risk reduction. The trial was stopped early because of clear benefit (Zannad et al., 2011).
Hypertension trials showed blood-pressure activity without a mortality endpoint
Eplerenone lowers systolic and diastolic blood pressure through aldosterone blockade. Hypertension trials demonstrated efficacy versus placebo and supported combination use with other antihypertensive agents. The hypertension indication has lower commercial differentiation because numerous inexpensive generic classes are available, including ACE inhibitors, angiotensin-receptor blockers, thiazide diuretics, calcium-channel blockers, and spironolactone.
What are the current eplerenone clinical-trial trends?
Active eplerenone development is limited compared with the drug’s earlier heart-failure program. Most current clinical activity involves investigator-sponsored studies, comparative effectiveness research, and use in populations with aldosterone-mediated disease rather than a new branded registration program.
Heart failure and chronic kidney disease
Eplerenone remains relevant in studies involving:
- Heart failure with reduced ejection fraction;
- Heart failure with preserved or mildly reduced ejection fraction;
- Chronic kidney disease and albuminuria;
- Resistant hypertension;
- Primary aldosteronism;
- Cardiovascular remodeling after myocardial infarction.
Large contemporary trials have shifted attention toward finerenone and sodium-glucose cotransporter-2 inhibitors. Finerenone has a stronger current development position in chronic kidney disease associated with type 2 diabetes, while eplerenone is established mainly through guideline-supported heart-failure use.
Comparative mineralocorticoid receptor antagonist research
Clinical research commonly compares eplerenone with spironolactone and finerenone on:
- Potassium elevation;
- Renal safety;
- Blood-pressure reduction;
- Left-ventricular remodeling;
- Hospitalization;
- Cardiovascular mortality;
- Albuminuria.
Eplerenone’s clinical advantage over spironolactone is tolerability. Its commercial disadvantage is that finerenone is positioned as a newer, nonsteroidal agent with a dedicated cardiorenal evidence base and active patent protection.
Trial development outlook
A new eplerenone registration program is commercially unlikely in the United States because generic products are available and the core composition and use patents have expired. Future trials are more likely to generate guideline evidence, comparative data, or support for off-label populations than to support a new originator launch.
When did eplerenone lose patent exclusivity?
The original eplerenone patent estate originated with Pharmacia and related entities and covered the compound and pharmaceutical uses. The principal U.S. compound patent is commonly identified as U.S. Patent No. 5,981,744. Its effective life ended in the mid-2010s after patent-term adjustment and regulatory exclusivity considerations.
| Exclusivity category |
Status |
| U.S. compound patent |
Expired |
| U.S. pediatric exclusivity |
Expired |
| Originator regulatory exclusivity |
Expired |
| Generic approval pathway |
ANDA approval available |
| Current U.S. market |
Generic competition |
The commercial loss of exclusivity occurred when generic manufacturers entered after the expiration of the principal patent and associated regulatory protections. Eplerenone therefore lacks the patent-based pricing protection available to newer therapies such as finerenone.
What is the Orange Book status of eplerenone?
The FDA Orange Book historically listed Inspra and generic eplerenone products with patent information associated with the originator product. With the expiration of the relevant patents, current commercial protection comes from manufacturing scale, formulary access, supply reliability, and distributor relationships rather than enforceable exclusivity.
Generic manufacturers typically enter through abbreviated new drug applications. A Paragraph IV certification would have been most relevant before the expiration of the principal patents. After expiration, market access depends mainly on FDA approval, product quality, manufacturing capacity, and commercial contracting.
What patent litigation and Paragraph IV challenges affected eplerenone?
Eplerenone’s major patent dispute period occurred before broad generic availability. The central legal issues involved validity, infringement, and the scope of compound and use claims. The most commercially relevant outcome was eventual generic entry after the loss of patent protection.
No active, originator-controlled U.S. patent barrier currently defines the eplerenone market. Litigation risk is more likely to involve:
- Manufacturing-process patents in specific jurisdictions;
- Product-quality or supply issues;
- ANDA-related disputes involving formulation or labeling;
- Contract and distribution matters;
- Patent disputes involving competing mineralocorticoid receptor antagonists rather than eplerenone itself.
Because eplerenone is a small-molecule generic, biosimilar litigation does not apply. The relevant pathway is the ANDA process, not the Biologics Price Competition and Innovation Act pathway.
Which formulations and manufacturing processes are protected?
Eplerenone is primarily supplied as immediate-release oral tablets in 25 mg and 50 mg strengths. The originator formulation used standard solid-dose pharmaceutical technology. Generic products can compete if they demonstrate pharmaceutical equivalence and bioequivalence to the reference listed drug.
The principal technical barriers are practical rather than exclusivity-based:
- Control of polymorphic and crystalline forms;
- Consistent tablet dissolution;
- Impurity control;
- Stability under long-term storage;
- Reliable sourcing of intermediates;
- Compliance with current good manufacturing practices;
- Validation of analytical methods.
Process patents may matter in individual jurisdictions, but they do not create a broad global barrier comparable with an unexpired compound patent. Suppliers with established active-pharmaceutical-ingredient capacity have a cost advantage over smaller entrants.
How strong is the eplerenone patent estate?
The current eplerenone patent estate is weak from an originator-protection perspective.
| Patent-estate factor |
Assessment |
| Core compound protection |
Expired |
| Broad therapeutic-use protection |
Expired or commercially ineffective |
| Formulation protection |
Limited commercial significance |
| Generic substitution barrier |
Low |
| Manufacturing complexity |
Moderate |
| Biosimilar risk |
Not applicable |
| Regulatory exclusivity |
Expired |
| Price protection |
Low |
The strongest remaining commercial assets are the brand name, physician familiarity, established clinical evidence, and distribution relationships. These assets do not prevent substitution.
How does eplerenone compare with spironolactone and finerenone?
| Attribute |
Eplerenone |
Spironolactone |
Finerenone |
| Drug class |
Steroidal MRA |
Steroidal MRA |
Nonsteroidal MRA |
| Selectivity |
High |
Lower |
High |
| Gynecomastia risk |
Lower than spironolactone |
Higher |
Low |
| Generic availability |
Yes |
Yes |
No broad generic U.S. competition |
| Key evidence |
Post-MI HFrEF; chronic HFrEF |
HFrEF; resistant hypertension |
Diabetic CKD and cardiovascular risk |
| Price position |
Low |
Very low |
Premium branded |
| Main safety issue |
Hyperkalemia |
Hyperkalemia and endocrine effects |
Hyperkalemia |
| Patent position |
Expired |
Expired |
Active originator protection |
Eplerenone occupies a middle position. It is more selective and often better tolerated than spironolactone, but it is less commercially differentiated than finerenone. Spironolactone remains the cost leader. Finerenone has the stronger commercial growth profile because of active cardiorenal development and branded reimbursement.
What is the eplerenone market size and revenue outlook?
Eplerenone revenue is fragmented across generic manufacturers and countries. Public companies generally do not report eplerenone sales as a separate material line item. The original Inspra franchise has been displaced by generic products, and current global revenue is best characterized as a mature, low-price market.
Market drivers
Demand is supported by:
- Growth in heart failure prevalence;
- Continued guideline use of MRAs in HFrEF;
- Increased diagnosis of resistant hypertension;
- Use in patients who cannot tolerate spironolactone’s endocrine effects;
- Expansion of generic access in emerging markets.
Market constraints
Growth is limited by:
- Generic price erosion;
- High use of low-cost spironolactone;
- Competition from finerenone;
- Increased use of SGLT2 inhibitors in heart failure and chronic kidney disease;
- Hyperkalemia monitoring requirements;
- Lack of active U.S. exclusivity;
- Limited originator-sponsored clinical development.
Projection, 2024-2029
| Scenario |
Expected market direction |
Main assumption |
| Base case |
Low-single-digit annual volume growth with flat-to-declining value |
More patients receive guideline therapy, while generic prices continue to fall |
| Upside case |
Mid-single-digit volume growth and stable value |
Wider use in HFpEF, resistant hypertension, and emerging markets |
| Downside case |
Flat or declining volume and high-single-digit value erosion |
Finerenone and SGLT2 inhibitors capture more cardiorenal use |
The value market is likely to underperform unit demand because price competition will continue. Growth opportunities for manufacturers are more likely to come from emerging-market registration, supply reliability, fixed-dose combinations, and contract manufacturing than from premium pricing.
What generic entry risks exist for eplerenone?
Generic launch risk is high because entry barriers are low and the market has no meaningful U.S. patent wall. New entrants face commercial risks rather than legal risks:
- Low average selling prices.
- Established generic suppliers with purchasing contracts.
- Pharmacy-benefit-manager and wholesaler concentration.
- Active-ingredient cost volatility.
- FDA manufacturing and inspection requirements.
- Limited differentiation between tablet products.
- Potential oversupply after multiple approvals.
A new entrant can still obtain share through reliable supply, competitive pricing, dual-source procurement, and coverage in markets where eplerenone is preferred for tolerability.
What is the FDA regulatory status of eplerenone?
Eplerenone remains an FDA-approved small-molecule drug. The reference product is Inspra, and generic eplerenone tablets are approved through the ANDA pathway. The principal regulatory safety issue is hyperkalemia.
The FDA label contraindicates use in specified patients with elevated serum potassium, significant renal impairment, or concomitant medicines that substantially increase eplerenone exposure or potassium levels. Strong CYP3A4 inhibitors are important because eplerenone is metabolized through CYP3A4 (FDA, 2023).
Key Takeaways
- Eplerenone is an established generic MRA for hypertension and heart failure.
- EPHESUS and EMPHASIS-HF provide the core mortality and hospitalization evidence.
- U.S. patent and regulatory exclusivity have expired.
- The market is governed by generic pricing and supply competition.
- Eplerenone has no biosimilar risk because it is a small molecule.
- Spironolactone is the low-cost competitor; finerenone is the principal newer branded competitor.
- Clinical research is shifting toward comparative safety, chronic kidney disease, HFpEF, and combination therapy.
- Unit demand may rise with heart-failure prevalence, but market value is likely to remain flat or decline.
- The strongest commercial opportunities are geographic expansion, dependable manufacturing, and differentiated supply contracts.
FAQs
Is eplerenone still under patent in the United States?
No. The principal U.S. patent protection and regulatory exclusivity for eplerenone have expired, allowing generic competition.
Is eplerenone included in heart-failure guidelines?
Yes. Eplerenone is included as a mineralocorticoid receptor antagonist option for eligible patients with heart failure with reduced ejection fraction, subject to renal-function and potassium monitoring.
Can eplerenone replace spironolactone?
It can be used as an alternative when spironolactone causes gynecomastia or other endocrine adverse effects. The choice depends on potassium, renal function, cost, formulary status, and clinical indication.
Is finerenone a direct replacement for eplerenone?
Finerenone overlaps mechanistically but has a different evidence and labeling profile. Its strongest commercial position is chronic kidney disease associated with type 2 diabetes, while eplerenone has established post-infarction and HFrEF indications.
What is the main manufacturing risk for generic eplerenone?
The principal risks are API sourcing, impurity control, tablet stability, dissolution performance, and regulatory compliance. Patent infringement is no longer the primary barrier in the U.S. market.
References
- U.S. Food and Drug Administration. (2023). Inspra (eplerenone) prescribing information. https://www.accessdata.fda.gov
- Pitt, B., Remme, W., Zannad, F., Neaton, J., Martinez, F., Roniker, B., Bittman, R., Hurley, S., Kleiman, J., & Gatlin, M. (2003). Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. New England Journal of Medicine, 348(14), 1309-1321. https://doi.org/10.1056/NEJMoa030207
- Zannad, F., McMurray, J. J. V., Krum, H., van Veldhuisen, D. J., Swedberg, K., Shi, H., Vincent, J., Pocock, S. J., & Pitt, B. (2011). Eplerenone in patients with systolic heart failure and mild symptoms. New England Journal of Medicine, 364(1), 11-21. https://doi.org/10.1056/NEJMoa1009492
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
- U.S. National Library of Medicine. (2024). ClinicalTrials.gov. https://clinicaltrials.gov/
